Form 4: Tonix Pharmaceuticals Director Stillwell Acquires Stock Options
SEC Form 4 Filing
Director Richard Stillwell acquired stock options in Tonix Pharmaceuticals Holding Corp. on May 23, 2024.
Summary
- Richard Stillwell, a director of Tonix Pharmaceuticals Holding Corp., filed a Form 4 on May 24, 2024.
- The filing reports a transaction that occurred on May 23, 2024.
- Stillwell acquired 104,621 stock options with an exercise price of $0.1745.
- These options vest on the earlier of May 23, 2025, or the Issuer's 2025 Annual Meeting of Stockholders and expire on May 23, 2034.
- Following the transaction, Stillwell directly owns 104,621 derivative securities.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing detailing an insider transaction. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in the pharmaceutical industry as part of executive compensation packages.
Key Dates
| Date | Description |
|---|---|
| 05/23/2024 | Date of transaction: Richard Stillwell acquired stock options. |
| 05/23/2025 | Options vest on the earlier of this date or the Issuer's 2025 Annual Meeting of Stockholders. |
| 05/23/2034 | Expiration date of the stock options. |
| 05/24/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.